{"id":3146,"date":"2024-03-09T19:15:13","date_gmt":"2024-03-09T18:15:13","guid":{"rendered":"https:\/\/solmed-clinic.com\/?post_type=ispitivanja&p=3146"},"modified":"2024-03-25T21:21:02","modified_gmt":"2024-03-25T20:21:02","slug":"multiple-sclerosis-okrelizumab-study","status":"publish","type":"ispitivanja","link":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/","title":{"rendered":"Multiple Sclerosis (Okrelizumab Study)"},"content":{"rendered":"

Location: Solmed Polyclinic (Zagreb)<\/h3>\n

Study Drug:<\/strong> Patients will be treated with either standard biologic therapy (okrelizumab) or a biosimilar of okrelizumab.<\/p>\n

Main Inclusion Criteria:<\/strong> Patients over 18 years old with an official diagnosis of relapsing-remitting multiple sclerosis, who have not been previously treated with the biologic therapy okrelizumab and, despite existing therapy, have symptoms of active disease.<\/p>\n

Status: Patient enrollment starting soon<\/span><\/h3>\n

Start of patient enrollment: April 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"

Study Drug: Patients will be treated with either standard biologic therapy (okrelizumab) or a biosimilar of okrelizumab.<\/p>\n","protected":false},"featured_media":0,"template":"","status_ispitivanja":[4],"podrucja":[125],"class_list":["post-3146","ispitivanja","type-ispitivanja","status-publish","hentry","status_ispitivanja-aktivno-ne-ukljucuje-pacijente","podrucja-neurology"],"acf":[],"yoast_head":"\nMultiple Sclerosis (Okrelizumab Study) - Solmed Clinic<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple Sclerosis (Okrelizumab Study) - Solmed Clinic\" \/>\n<meta property=\"og:description\" content=\"Study Drug: Patients will be treated with either standard biologic therapy (okrelizumab) or a biosimilar of okrelizumab.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Solmed Clinic\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/solmedgrupa\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-25T20:21:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/\",\"url\":\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/\",\"name\":\"Multiple Sclerosis (Okrelizumab Study) - Solmed Clinic\",\"isPartOf\":{\"@id\":\"https:\/\/solmed-clinic.com\/#website\"},\"datePublished\":\"2024-03-09T18:15:13+00:00\",\"dateModified\":\"2024-03-25T20:21:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Po\u010detna stranica\",\"item\":\"https:\/\/solmed-clinic.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Multiple Sclerosis (Okrelizumab Study)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/solmed-clinic.com\/#website\",\"url\":\"https:\/\/solmed-clinic.com\/\",\"name\":\"Solmed Clinic\",\"description\":\"Solutions in medicine\",\"publisher\":{\"@id\":\"https:\/\/solmed-clinic.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/solmed-clinic.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/solmed-clinic.com\/#organization\",\"name\":\"Solmed Clinic\",\"url\":\"https:\/\/solmed-clinic.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/solmed-clinic.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/solmed-clinic.com\/wp-content\/uploads\/2020\/04\/solmed-small.svg\",\"contentUrl\":\"https:\/\/solmed-clinic.com\/wp-content\/uploads\/2020\/04\/solmed-small.svg\",\"width\":482,\"height\":77,\"caption\":\"Solmed Clinic\"},\"image\":{\"@id\":\"https:\/\/solmed-clinic.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/solmedgrupa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Multiple Sclerosis (Okrelizumab Study) - Solmed Clinic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/","og_locale":"en_US","og_type":"article","og_title":"Multiple Sclerosis (Okrelizumab Study) - Solmed Clinic","og_description":"Study Drug: Patients will be treated with either standard biologic therapy (okrelizumab) or a biosimilar of okrelizumab.","og_url":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/","og_site_name":"Solmed Clinic","article_publisher":"https:\/\/www.facebook.com\/solmedgrupa","article_modified_time":"2024-03-25T20:21:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/","url":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/","name":"Multiple Sclerosis (Okrelizumab Study) - Solmed Clinic","isPartOf":{"@id":"https:\/\/solmed-clinic.com\/#website"},"datePublished":"2024-03-09T18:15:13+00:00","dateModified":"2024-03-25T20:21:02+00:00","breadcrumb":{"@id":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/solmed-clinic.com\/en\/ispitivanja\/multiple-sclerosis-okrelizumab-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Po\u010detna stranica","item":"https:\/\/solmed-clinic.com\/en\/"},{"@type":"ListItem","position":2,"name":"Multiple Sclerosis (Okrelizumab Study)"}]},{"@type":"WebSite","@id":"https:\/\/solmed-clinic.com\/#website","url":"https:\/\/solmed-clinic.com\/","name":"Solmed Clinic","description":"Solutions in medicine","publisher":{"@id":"https:\/\/solmed-clinic.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/solmed-clinic.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/solmed-clinic.com\/#organization","name":"Solmed Clinic","url":"https:\/\/solmed-clinic.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/solmed-clinic.com\/#\/schema\/logo\/image\/","url":"https:\/\/solmed-clinic.com\/wp-content\/uploads\/2020\/04\/solmed-small.svg","contentUrl":"https:\/\/solmed-clinic.com\/wp-content\/uploads\/2020\/04\/solmed-small.svg","width":482,"height":77,"caption":"Solmed Clinic"},"image":{"@id":"https:\/\/solmed-clinic.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/solmedgrupa"]}]}},"_links":{"self":[{"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/ispitivanja\/3146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/ispitivanja"}],"about":[{"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/types\/ispitivanja"}],"version-history":[{"count":3,"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/ispitivanja\/3146\/revisions"}],"predecessor-version":[{"id":3332,"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/ispitivanja\/3146\/revisions\/3332"}],"wp:attachment":[{"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/media?parent=3146"}],"wp:term":[{"taxonomy":"status_ispitivanja","embeddable":true,"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/status_ispitivanja?post=3146"},{"taxonomy":"podrucja","embeddable":true,"href":"https:\/\/solmed-clinic.com\/en\/wp-json\/wp\/v2\/podrucja?post=3146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}